Evidence map›Paper›PMID 19307010›Full record

ArticleVirology2009

Receptor usage of a newly emergent adenovirus type 14.

Hongjie Wang, Sebastian Tuve, Dean D Erdman, André Lieber

Open access · greenAbstract read
In one paragraph

Article in Virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hongjie WangUniversity of Washington, Seattle, 98195, USA.
Sebastian Tuve
Dean D Erdman
André Lieber
University of Washington · USCenters for Disease Control and Prevention · USUniversity of Washington Medical Center · US

Funding

Evaluation of Vectors based on group B adenovirusesR01CA144057 · NCI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2010 to 2014
$2.5M
Evaluation of vectors based on group B adenovirusesR01HL078836 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2005 to 2009
$1.4M
NCI NIH HHS R01 CA144057NHLBI NIH HHS R01 HL078836PHS HHS HLA078836
6 · The paper itself

Abstract

Recently, cases of severe respiratory illness in military and civilian populations have been associated with a new genomic variant of adenovirus (Ad) serotype 14, designated Ad14a. Compared to the Ad14 reference strain (de Wit), this new virus had a deletion of two amino acid residues in the fiber protein knob. Here we tested whether this mutation changed receptor usage of Ad14a compared to Ad14-de Wit. Competition studies with radio-labeled viruses revealed that both Ad14-de Wit and Ad14a used the same receptor which is hitherto unknown. We also found that recombinant fiber knobs only partially blocked attachment of Ad14a, indicating that virus capsid proteins other than the fiber are involved in infection.

Indexed as

Adenoviruses, HumanAdenovirus Infections, HumanAmino Acid SequenceAntigens, ViralCapsid ProteinsCell LineHumansMolecular Sequence DataPoint MutationReceptors, VirusRecombinant ProteinsSequence AlignmentVirus AttachmentAntigens, ViralCapsid Proteinshexon capsid protein, AdenovirusReceptors, VirusRecombinant Proteins

Identifiers

PMID19307010
PMCPMC2674115
OpenAlexW2052409351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.